Top

Published in:

29-01-2024 | Heart Failure | Letter to the Editor

Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction

Authors: Takuro Washio, Sarah L. Hissen, Ryosuke Takeda, John D. Akins, Denis J. Wakeham, Tiffany Brazile, Christopher M. Hearon Jr, James P. MacNamara, Satyam Sarma, Benjamin D. Levine, Paul J. Fadel, Qi Fu

Published in: Clinical Autonomic Research | Issue 1/2024

Excerpt

The prevalence of heart failure (HF) with preserved ejection fraction (HFpEF) continues its yearly increase in the USA and now surpasses that of HF with reduced ejection fraction (HFrEF) [9]. HFpEF is associated with high morbidity, mortality, and economic cost. Medications established as part of guideline-directed medical therapy have reduced hospitalization rates and cardiovascular morbidity and mortality for patients with HFrEF [9]. However, most current drug therapies remain unsuccessful in improving clinical outcomes in patients with HFpEF. Therefore, other pharmacotherapies are urgently needed to effectively treat HFpEF. …

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M, Investigators EM-PT (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461CrossRefPubMed

Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, Roveda F, de Matos LN, Braga AM, Middlekauff HR, Negrao CE (2009) Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 135:302–307CrossRefPubMed

Belli M, Barone L, Bellia A, Sergi D, Lecis D, Prandi FR, Milite M, Galluccio C, Muscoli S, Romeo F, Barilla F (2022) Treatment of HFpEF beyond the SGLT2-is: does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients? Int J Mol Sci 23:14598CrossRefPubMedPubMedCentral

Bruno RM, Daghini E, Ghiadoni L, Sudano I, Rugani I, Varanini M, Passino C, Emdin M, Taddei S (2012) Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am J Clin Nutr 96:302–308CrossRefPubMed

Diaz HS, Toledo C, Andrade DC, Marcus NJ, Del Rio R (2020) Neuroinflammation in heart failure: new insights for an old disease. J Physiol 598:33–59CrossRefPubMed

Dong M, Wen S, Zhou L (2022) The relationship between the blood-brain-barrier and the central effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors. Diabetes Metab Syndr Obes 15:2583–2597CrossRefPubMedPubMedCentral

Fonkoue IT, Le NA, Kankam ML, DaCosta D, Jones TN, Marvar PJ, Park J (2019) Sympathoexcitation and impaired arterial baroreflex sensitivity are linked to vascular inflammation in individuals with elevated resting blood pressure. Physiol Rep 7:e14057CrossRefPubMedPubMedCentral

Hamaoka T, Murai H, Hirai T, Sugimoto H, Mukai Y, Inoue O, Takashima S, Kato T, Takata S, Usui S, Sakata K, Kawashiri MA, Takamura M (2021) Different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure. J Am Heart Assoc 10:e022637CrossRefPubMedPubMedCentral

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol 79:e263–e421CrossRefPubMed

10.

Heusser K, Tank J, Diedrich A, Fischer A, Heise T, Jordan J (2023) Randomized trial comparing SGLT2 inhibition and hydrochlorothiazide on sympathetic traffic in type 2 diabetes. Kidney Int Rep 8:2254–2264CrossRefPubMedPubMedCentral

11.

Lambert GW, Schlaich MP, Eikelis N, Lambert EA (2019) Sympathetic activity in obesity: a brief review of methods and supportive data. Ann N Y Acad Sci 1454:56–67ADSCrossRefPubMed

12.

Pauza AG, Thakkar P, Tasic T, Felippe I, Bishop P, Greenwood MP, Rysevaite-Kyguoliene K, Ast J, Broichhagen J, Hodson DJ, Salgado HC, Pauza DH, Japundzic-Zigon N, Paton JFR, Murphy D (2022) GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res 130:694–707CrossRefPubMedPubMedCentral

13.

Sarma S, MacNamara JP, Balmain BN, Hearon CM Jr, Wakeham DJ, Tomlinson AR, Hynan LS, Babb TG, Levine BD (2023) Challenging the hemodynamic hypothesis in heart failure with preserved ejection fraction: is exercise capacity limited by elevated pulmonary capillary wedge pressure? Circulation 147:378–387CrossRefPubMed

14.

Wen S, Nguyen T, Gong M, Yuan X, Wang C, Jin J, Zhou L (2021) An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is). Diabetes Metab Syndr Obes 14:2955–2972CrossRefPubMedPubMedCentral

Title: Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction
Authors: Takuro Washio
Sarah L. Hissen
Ryosuke Takeda
John D. Akins
Denis J. Wakeham
Tiffany Brazile
Christopher M. Hearon Jr
James P. MacNamara
Satyam Sarma
Benjamin D. Levine
Paul J. Fadel
Qi Fu
Publication date: 29-01-2024
Publisher: Springer Berlin Heidelberg
Keyword: Heart Failure
Published in: Clinical Autonomic Research / Issue 1/2024
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI: https://doi.org/10.1007/s10286-023-01013-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Comment to the article “Standing tests lack reliability to diagnose all adolescents who have postural tachycardia syndrome”

Acknowledgment to Reviewers

Clinical Autonomic Research: welcome to 2024

Anxiety and dysautonomia symptoms in patients with a NaV1.7 mutation and the potential benefits of low-dose short-acting guanfacine

Effect of levodopa on postural blood pressure changes in Parkinson disease: a randomized crossover study

In Memoriam: Carl-Albrecht Haensch, M.D.